FILING ANALYSIS · TUESDAY, NOVEMBER 17

INTERPACE BIOSCIENCES, INC. IDXG — 8-K: Results of Operations and Financial Condition

positive

Interpace Biosciences reported Q3 revenue of $10.4 million, an 18% year-over-year increase, with a loss from continuing operations of $1.5 million, and produced Adjusted EBITDA of $2.1 million, or 20% of revenue. The company's thyroid business showed a 7% year-over-year increase in volume and an 18% year-over-year increase in revenue.

The filing

8-K - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)

Read the filing on SEC EDGAR →

How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.

Get filings like this every market day

The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.

Subscribe free →
All analyses · Earnings today · Latest brief · Track record
© 2026 Dutchcode B.V. · Built by
Blinkof.ai verified — grade A+